Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation

Journal of Infection

Volumn 59, Issue 3, 2009, Pages 207-212

  Kawai, Naoki ^a   Ikematsu, Hideyuki ^a,b   Iwaki, Norio ^a   Kondou, Kunio ^a   Hirotsu, Nobuo ^a   Kawashima, Takashi ^a   Maeda, Tetsunari ^a   Tanaka, Osame ^a   Doniwa, Ken ichi ^a   Kashiwagi, Seizaburo ^a  

^a Japan Physician's Association   (Japan)

^b Hara Doi Hospital   (Japan)

Author keywords

Influenza A(H1N1); Mutation; Neuraminidase; Oseltamivir; Resistance

Indexed keywords

OSELTAMIVIR; SIALIDASE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; FEVER; GENE MUTATION; HUMAN; IC 50; INFLUENZA; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; SEASONAL VARIATION; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BODY TEMPERATURE; CHILD; CHILD, PRESCHOOL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69749088504     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.07.002     Document Type: Article

References (32)

1. Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D., et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 283 (2000) 1016-1024
2. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
3. Nicholson K.G., Aoki F.Y., Osterhaus A.D., Trottier S., Carewicz O., Mercier C.H., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 355 (2000) 1845-1850
4. McClellan K., and Perry C.M. Oseltamivir: a review of its use in influenza. Drugs 61 (2001) 263-283
5. Cooper N.J., Sutton A.J., Abrams K.R., Wailoo A., Turner D., and Nicholson K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systemic review and meta-analyses of randomised controlled trials. BMJ 326 (2003) 1235-1239
6. Kawai N., Ikematsu H., Iwaki N., Satoh I., Kawashima T., Maeda T., et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 40 (2005) 1309-1316
7. Kawai N., Ikematsu H., Iwaki N., Maeda T., Satoh I., Hirotsu N., et al. A Comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 43 (2006) 439-444
8. Kawai N., Ikematsu H., Iwaki N., Kawashima T., Maeda T., Mitsuoka S., et al. Longer virus shedding in influenza B than in influenza A among outpatients treated with oseltamivir. J Infect 55 (2007) 267-272
9. Kawai N., Ikematsu H., Iwaki N., Maeda T., Kanazawa H., Kawashima T., et al. A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. J Infect 56 (2008) 51-57
10. World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir 2008-2009 influenza season (22 January 2009). http://www.who.int/csr/disease/influenzA(H1N1)20090122_final.pdf
11. Aoki F.Y., Boivin G., and Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 12 (2007) 603-616
12. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453 (2008) 1258-1261
13. Lackenby A., Hungnes O., Dudman S.G., Meijer A., Paget W.J., Hay A.J., et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eurosurveillance 13 (2008) 1-2
14. Wang M.Z., Tai C.Y., and Mendel D.B. Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 46 (2002) 3809-3816
15. Abed Y., Goyette N., and Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A(H1N1) virus. Antivir Ther 9 (2004) 577-581
16. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al., Novel Swine-Origin Influenza A(H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360 (2009) 2605-2615
17. Fraser C., Donnelly C.A., Cauchemez S., Hanage W.P., Van Kerkhove M.D., Hollingsworth T.D., et al. Pandemic potential of a strain of Influenza A (H1N1): early findings. Science 324 (2009) 1557-1561
18. Centers for Disease Control and Prevention (CDC). MMWR update: novel influenza A (H1N1) virus infections - worldwide vol. 58 (May 6, 2009), Centers for Disease Control and Prevention (CDC) p. 453-8
19. Neumann G., Noda T., and Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459 (2009) 931-939
20. Rungrotmongkol T., Intharathep P., Malaisree M., Nunthaboot N., Kaiyawet N., Sompornpisut P., et al. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 31 (2009) 390-394
21. Gubareva L.V., Webster R.G., and Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 53 (2002) 47-61
22. Potier M., Mameli L., Belisle M., Dallaire L., and Melancon S.B. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-d-N-acetylneuraminate) substrate. Anal Biochem 94 (1979) 287-296
23. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 360 (2009) 953-956
24. Tamura D., Mitamura K., Yamazaki M., Fujino M., Nirasawa M., Kimura K., et al. Oseltamivir-resistant influenza A viruses circulating in Japan. J Clin Microbiol 47 (2009) 1424-1427
25. Centers for Disease Control and Prevention (CDC). Issues interim recommendations for the use of influenza antiviral medications in the setting of oseltamivir resistance among circulating influenza A (H1N1) Viruses, 2008-09 Influenza Season (December 19, 2008), Health Alert Network. http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279
26. Poland G.A., Jacobson R.M., and Ovsyannikova I.G. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 48 (2009) 1254-1256
27. Kaji M., Watanabe A., and Aizawa H. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients. Respirology 8 (2003) 231-233
28. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301 (2009) 1034-1041
29. Hauge S.H., Dudman S., Borgen K., Lackenby A., and Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15 (2009) 155-162
30. Oo C., Barrett J., Hill G., Mann J., Dorr A., Dutkowski R., et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatric Drugs 3 (2001) 229-236
31. van der Vries E., van den Berg B., and Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 359 (2008) 1074-1076
32. Gooskens J., Jonges M., Claas E.C., Meijer A., van den Broek P.J., and Kroes A.M. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 301 (2009) 1042-1046